Abstract
Abstract Background Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients with early triple-negative breast cancer. Whether ...
Cite
CITATION STYLE
APA
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., … O’Shaughnessy, J. (2020). Pembrolizumab for Early Triple-Negative Breast Cancer. New England Journal of Medicine, 382(9), 810–821. https://doi.org/10.1056/nejmoa1910549
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free